CA2518119A1 - Inhibition d'apoptose induite par un anticorps tansmembranaire - Google Patents

Inhibition d'apoptose induite par un anticorps tansmembranaire Download PDF

Info

Publication number
CA2518119A1
CA2518119A1 CA002518119A CA2518119A CA2518119A1 CA 2518119 A1 CA2518119 A1 CA 2518119A1 CA 002518119 A CA002518119 A CA 002518119A CA 2518119 A CA2518119 A CA 2518119A CA 2518119 A1 CA2518119 A1 CA 2518119A1
Authority
CA
Canada
Prior art keywords
antibody
peptide
mts
caspase
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002518119A
Other languages
English (en)
Inventor
Heinz Kohler
Sybille Muller
Thomas L. Brown
Yunfeng Zhao
Alton C. Morgan, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innexus Biotechnology International Ltd Canada
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2518119A1 publication Critical patent/CA2518119A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002518119A 2003-03-05 2004-03-05 Inhibition d'apoptose induite par un anticorps tansmembranaire Abandoned CA2518119A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45198003P 2003-03-05 2003-03-05
US60/451,980 2003-03-05
PCT/US2004/006911 WO2004078146A2 (fr) 2003-03-05 2004-03-05 Inhibition d'apoptose induite par un anticorps tansmembranaire

Publications (1)

Publication Number Publication Date
CA2518119A1 true CA2518119A1 (fr) 2004-09-16

Family

ID=32962675

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002518119A Abandoned CA2518119A1 (fr) 2003-03-05 2004-03-05 Inhibition d'apoptose induite par un anticorps tansmembranaire

Country Status (5)

Country Link
EP (1) EP1605893A4 (fr)
JP (1) JP2006522122A (fr)
KR (1) KR20060006775A (fr)
CA (1) CA2518119A1 (fr)
WO (1) WO2004078146A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004049479A1 (de) * 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
US8361462B2 (en) 2005-09-01 2013-01-29 National Research Council Of Canada Anti-apoptotic protein antibodies
IT1392238B1 (it) * 2008-12-02 2012-02-22 Fond Santa Lucia Uso della caspasi-3 per la malattia dell'alzheimer
CA2758378A1 (fr) * 2009-04-14 2010-10-21 Trojan Technologies Ltd. Molecules therapeutiques antennapedia-anticorps et leurs procedes d'utilisation
NZ729747A (en) * 2013-03-15 2020-03-27 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US10456475B2 (en) 2015-02-03 2019-10-29 Kennsaw State University Research and Service Foundation, Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
US10435446B2 (en) 2015-06-03 2019-10-08 Kennesaw State University Research and Service Foundation Inc. Cell penetrating protein adaptor molecules and their application in research and medicine
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
EP3411387A4 (fr) 2016-02-03 2019-12-04 Kennesaw State University Research And Services Foundation Inc. Molécules signal utiles en tant qu'agents de pénétration cellulaire

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2813630B2 (ja) * 1987-02-20 1998-10-22 ジェネンテク，インコーポレイテッド ヒト免疫不全ウイルスのエンベロープポリペプチドおよびその抗体
US5242824A (en) * 1988-12-22 1993-09-07 Oncogen Monoclonal antibody to human carcinomas
US6316003B1 (en) * 1989-12-21 2001-11-13 Whitehead Institute For Biomedical Research Tat-derived transport polypeptides
US6248558B1 (en) * 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
DK1244705T3 (da) * 1999-12-06 2010-05-31 Agensys Inc Serpentintransmembrane antigener udtryk i human prostatacancere og anvendelser deraf
GB0003284D0 (en) * 2000-02-15 2000-04-05 Secr Defence Brit Anti-viral therapy
AU2001293533A1 (en) * 2000-09-08 2002-03-22 Merck Frosst Canada & Co. Gamma-ketoacid dipeptides as inhibitors of caspase-3
JP2002355077A (ja) * 2001-02-23 2002-12-10 Takeda Chem Ind Ltd カスパーゼ３阻害剤
US20060233790A1 (en) * 2002-03-22 2006-10-19 Shiroh Futaki Immunoglobulin/hydrophilic peptide complexes

Also Published As

Publication number Publication date
KR20060006775A (ko) 2006-01-19
EP1605893A2 (fr) 2005-12-21
JP2006522122A (ja) 2006-09-28
WO2004078146A3 (fr) 2006-01-05
EP1605893A4 (fr) 2008-08-13
WO2004078146A2 (fr) 2004-09-16

Similar Documents

Publication Publication Date Title
US20120135012A1 (en) Trans-membrane-antibody induced inhibition of apoptosis
US6344203B1 (en) Mimicking peptides in cancer therapy
AU2016316281B2 (en) Molecular constructs for treating rejection reaction in transplantation
US5869636A (en) Immunoreactive peptide sequence from a 43 kD human cancer antigen
CA2890265C (fr) Proteines de liaison a un antigene et leur utilisation comme produit d'adressage pour le traitement du cancer
US20070031445A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
JPH04501719A (ja) ポリペプチド
Lai et al. Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1
CA2518119A1 (fr) Inhibition d'apoptose induite par un anticorps tansmembranaire
WO2002097041A2 (fr) Proteines hybrides constituees de peptides et d'anticorps biologiquement actifs
JP2009544291A (ja) ムチン１（ｍｕｃ１）ｔ細胞エピトープ由来ペプチド含有癌ワクチン
EP1182210A1 (fr) Epitopes de l'antigène MUC1 associé aux tumeurs
Polli et al. Cell penetrating peptides conjugated to anti-carcinoembryonic antigen “catch-and-release” monoclonal antibodies alter plasma and tissue pharmacokinetics in colorectal cancer xenograft mice
WO1998058541A1 (fr) Modulation de l'apoptose
WO1992021767A1 (fr) Me20: anticorps monoclonaux et antigene contre le melanome humain
US10421808B2 (en) Bak binding proteins
US20210130489A1 (en) Novel peptide-based compounds for use in the prevention, treatment and/or detection of cancer
US20190202885A1 (en) TauT (taurine transporter) peptide cancer vaccine
Hollingsworth Sanderson et al.
Sharma Generation of single chain Fv protein a fusion molecules for melanoma therapy

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued